Columbia University

BioLineRx's CheMo4METPANC Phase 2 pilot study demonstrated a 64% overall response rate and 91% disease control rate in first-line pancreatic cancer patients treated with motixafortide combination therapy.

Brooklyn Health secured $6.5 million in seed funding led by HealthX Ventures to advance its AI-powered clinical trial measurement technology for central nervous system disorders.

Genflow Biosciences has successfully progressed its SIRT6 variant patent application through the European Patent Office's Supplementary Search Report without additional questions, strengthening its intellectual property position.

Scientists have developed a groundbreaking antivenom using antibodies from Tim Friede, who voluntarily endured over 200 snake bites and 700 venom injections over nearly 20 years.

BPGbio's novel CoQ10 formulation BPM31510 successfully crosses the blood-brain barrier and delivers CoQ10 to the cerebellum, potentially addressing ataxic symptoms in primary CoQ10 deficiency.

Colorado becomes the second U.S. state after Oregon to implement legal psilocybin therapy, with licensing applications beginning this week for treating conditions like PTSD and depression.

A prominent researcher challenges the prevailing view that extracellular amyloid plaques are the primary cause of Alzheimer's disease, advocating for further investigation into intracellular pathologies.

Researchers have engineered probiotic bacteria to target and destroy cancer cells by activating the immune system, offering a new personalized cancer vaccine approach.

Bret Rutherford, formerly of Columbia University, was found to have committed research misconduct by falsely reporting subject eligibility in late-life depression studies.

Two out of four U.S. treatment trials demonstrated the efficacy of IV ceftriaxone on primary and/or secondary outcome measures for post-treatment Lyme fatigue.